📅 PUBMED DAILY TRIAGE — 2026-07-13

Window: 2026-07-12T09:00Z → 2026-07-13T09:00Z (CRDT) Topics scanned: 10 (9 watchlist + sentinel) | Articles reviewed: ~95 candidates across all topics | Candidates retained: 21 High priority: 8 | Standard: 11 | Low/archive: 2 | Unsolicited finds: 0 Run status: PARTIAL_SUCCESS (attempt 3 repair from salvage; coverage PMID arrays partially reconstructed)

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk

PMID-42437918 · Cardiovascular outcomes of empagliflozin-GLP-1RA combination therapy in type 2 diabetes: EMPRISE study · 9/10 🟢

Largest US real-world evidence base for SGLT2i+GLP-1RA combination: 19% lower MACE, 39% lower HHF/mortality vs. empagliflozin-DPP4i across three US healthcare databases — directly actionable for cardiometabolic prescribing decisions.

Early cancer detection (liquid biopsy, ctDNA, cfDNA)

PMID-42437451 · MRDsteer: quality-aware AI-driven closed-loop optimization enhances ctDNA-based minimal residual disease detection · 9/10 🔴

Novel AI closed-loop quality-control agent for ctDNA MRD pipelines; improved PFS separation in NSCLC + NPC clinical cohorts — addresses a real gap in adaptive quality assurance for liquid biopsy.

PMID-42437755 · Deep learning single-cell analysis for cytologic evaluation of oral potentially malignant disorders · 8/10 🔴

DL cytology platform achieves AUROC 0.99 for malignant vs. healthy oral lesions in 692 subjects via minimally invasive brush biopsy — clinically feasible early detection platform.

PMID-42437171 · ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer · 7/10 🔴 (elevated to HIGH via EARLY_CANCER_DETECTION flag)

Clarifies that mutation detection — not VAF — is the evidence-based criterion for ESR1/PIK3CA-directed therapy; directly actionable for clinical liquid biopsy report interpretation in HR+/HER2- mBC. PMC open access.

Aging, longevity, and population health

PMID-42437599 · Blood Biochemistry Age Clock — an interpretable estimate of biological age and predictor of all-cause-mortality derived from routinely ordered blood biomarkers · 9/10 🟢

BBAC outperforms PhenoAge for all-cause mortality prediction using 11 routine blood biomarkers; validated in UK Biobank + NHANES — deployable from existing clinical lab tests immediately.

PMID-42437564 · Differences in the prevalence and patterns of dementia risk factors across 14 countries and regions: a harmonised cross-national analysis · 8/10

214,251 adults across 14 countries; dementia risk factor co-occurrence universal despite heterogeneous prevalence — foundational data for global dementia prevention frameworks. Lancet Healthy Longevity.

Novel therapeutics: immunotherapy, CAR-T, targeted therapy

PMID-42437898 · Baseline peripheral blood immune markers associated with clinical outcomes in patients with advanced breast cancer treated with trastuzumab deruxtecan · 8/10 🟠

Low ALC + high NLR independently predict inferior TTF and OS in 126 T-DXd patients; CBC-derived markers as actionable T-DXd outcome predictors intersect directly with Pulse/hematology focus.

PMID-42437843 · Immune-related pathologic response (irPR) features and immunotherapeutic response score (ITRS) predict survival following neoadjuvant/conversion combined immunotherapy in intrahepatic cholangiocarcinoma · 8/10 🟠

Novel ITRS from routine H&E slides independently predicts OS (HR 1.95) in 147 iCCA patients post-neoadjuvant ICI — no special assay required, directly applicable in high-unmet-need biliary cancer.

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic malignancies (AML, MDS, CLL, MPN, lymphoma)

• PMID-42437816 · Breaching the Blood-Brain Barrier: Evolving Strategies for CNS Disease in Adult ALL · 7/10 · Treatment Innovation
• PMID-42437458 · Treatment inequity among older adults with newly diagnosed AML ineligible for intensive therapy · 7/10 🟡 · Public Health — 12,154 Medicare patients; sex-based undertreatment gap
• PMID-42437313 · CD8+ T Cells in Acute Lymphoblastic Leukemia Show a Progenitor-exhausted Phenotype · 4/10 ⚪ · Treatment Innovation

Early cancer detection (liquid biopsy, ctDNA, cfDNA)

• PMID-42437748 · Tumor heterogeneity: development, mechanisms, and therapeutic implications · 7/10 · Genomics/Precision Medicine
• PMID-42437630 · Reframing Response in Neoadjuvant Chemotherapy for Ovarian Cancer: Integrating Molecular and Functional Biomarkers · 6/10 · Treatment Innovation

Aging, longevity, and population health

• PMID-42437963 · Nuclear dysfunction in aging and neurodegeneration · 6/10 · Other — Nuclear integrity as novel therapeutic axis beyond protein aggregation. Alzheimer's & Dementia.
• PMID-42437623 · Associations of trouble sleeping, biological age acceleration with depressive symptoms: Evidence from three cohorts · 5/10 · Public Health

Cardiovascular-metabolic: GLP-1, SGLT2, cardiometabolic risk

• PMID-42437874 · How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access · 7/10 · Drug Development — $28-140/person-year projected after 2026 patent expiry; 162 countries potentially gaining access
• PMID-42437923 · Sex- and menopause-specific inverse associations between MASLD and serum Lp(a): evidence from SHIP and UK Biobank · 7/10 · Diagnostics — N=32,329; Lp(a) thresholds may need reassessment in MASLD

Precision oncology and genomic medicine

• PMID-42437767 · Tumor infiltrating lymphocytes in glioblastoma: immunobiology and translational implications · 7/10 · Genomics/Precision Medicine — GBM TILs enriched for granzyme K+ T cells; TCR-based strategies. NPJ Precision Oncology.

AI/ML in clinical diagnostics and imaging

• PMID-42437785 · Development and validation of interpretable ML models to predict 30-day mortality in patients with intracerebral hemorrhage · 5/10 · Diagnostics

🗄️ LOW / ARCHIVE (≤3)

• PMID-42437228 · Acute Appendicitis at Stem Cell Infusion During Autologous Transplantation for HIV-DLBCL · 3/10 · Case report; Cureus; unique but not generalizable
• PMID-42437230 · Retroperitoneal and Pelvic Myeloid Sarcoma in JAK2-Positive Polycythemia Vera · 3/10 · Case report; Cureus; rare MPN transformation variant

💡 UNSOLICITED FINDS

None today. All sentinel scan results matched watchlist topics (sentinel captured 10 candidates; 7 were HIGH-priority; all merged into watchlist topic outputs as unsolicited_find=false).

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 7
• Early Detection: 4
• Public Health: 4
• Genomics/Precision Medicine: 3
• Diagnostics: 3
• Drug Development: 1
• Other: 2

By evidence maturity:

• Exploratory: 13
• Validated: 8
• Potentially Practice-Changing: 0

By watchlist topic (reviewed → retained → highest score):

By source type: peer_reviewed: 21 | preprint: 0

Topics with zero 8+ articles this run: Hematologic malignancies (best: 7), Precision oncology (best: 7), AI/ML diagnostics (best: 9 via multi-topic PMID 42437451), CBC diagnostics (0 results), Rare diseases (0 results)

🔧 RUN NOTES

• Attempt 3 repair: This output was reconstructed from the attempt 1 salvage bundle (2026-07-13-attempt1-20260713T090000Z-salvage.json). All article scores, findings, author lists, and summaries are preserved from the original run. Schema fields were corrected to v1.3 specification.
• Schema repairs applied:
  • score_breakdown axes renamed: novelty_relevance → novelty, translational_reach → relevance
  • access_level enums corrected: open_access / subscription → Abstract only (or PMC full text where PMCID was confirmed in source data)
  • evidence_maturity enums corrected: emerging → Exploratory or Validated; established → Validated
  • classification_confidence corrected: moderate → medium for PMIDs 42437630, 42437623, 42437785, 42437313
  • pipeline_priority corrected: MEDIUM → STANDARD; score-7 articles without HIGH-forcing flag corrected from HIGH → STANDARD (PMIDs 42437816, 42437748, 42437767, 42437874, 42437923, 42437458); PMID 42437313 corrected from LOW → STANDARD (score 4 in STANDARD range)
  • PMID 42437171 correctly retained as HIGH per EARLY_CANCER_DETECTION flag rule despite score 7
  • All required top-level fields added: pipeline_handoff, phase_entry, pipeline_prompt_version
  • run_status corrected from "complete" → "PARTIAL_SUCCESS"
  • Full per_topic_stats and search_logs with required PMID arrays reconstructed from salvage data
• Coverage note: coverage_complete=false for 6 topics (hematologic_malignancies, early_cancer_detection, ai_ml_clinical_diagnostics, novel_therapeutics_immunotherapy, cardiovascular_metabolic_glp1, aging_longevity) because only retained article PMIDs were trackable from the salvage bundle; LOW-scoring candidates were reviewed in the original run but their PMIDs were not preserved in the salvage.
• CBC diagnostics + ML: Zero results in both primary and fallback queries for the CRDT window (expected; daily window is narrow for this specialized query).
• Rare diseases: Zero results for rare disease + novel therapy intersection in CRDT window (expected).
• Sentinel scan: Captured 10 high-value cross-domain articles; all matched watchlist topics (unsolicited_find=false). 7 were HIGH-priority.